Seegene

Seegene P/B

The P/B (Price-to-Book Ratio) of Seegene (096530.KQ) as of Oct 28, 2026 is 1.04. In the previous year, P/B (Price-to-Book Ratio) was 1.08 — a change of -3.63% (lower).

P/B

1.04

YoY

-3.63%

Last updated:

P/B (Price-to-Book Ratio) of Seegene is 2025 1.04 . P/B (Price-to-Book Ratio) of Seegene was 2024 1.08 . It decreases by -3.63% lower compared to the previous year.

The Seegene P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
8.23 KRW
Jan 1, 2019
6.91 KRW
Jan 1, 2020
1.63 KRW
Jan 1, 2021
0.97 KRW
Jan 1, 2022
0.92 KRW
Jan 1, 2023
1.03 KRW
Jan 1, 2024
1.08 KRW
Jan 1, 2025
1.04 KRW
The Seegene P/B history
YEARP/BYoY
1.04-3.63%
1.08+5.01%
1.03+11.68%
0.92-5.78%
0.97-40.33%
1.63-76.36%
6.91-16.07%
8.23-2.33%
8.43+13.54%
7.42-4.85%
7.80-29.86%
11.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

P/B (Price-to-Book Ratio) of Seegene is 1.04 in 2025.

P/B (Price-to-Book Ratio) of Seegene changed from 1.08 to 1.04, representing a -3.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Seegene since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Seegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Seegene

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Seegene